Physician profile
Jennifer Van Nguyen
NPI 1851585384
$3,184.73
in general payments reported to CMS, 2019-2025
26 companies · $1,474 in 2025
The $1,474 reported for 2025 was more than what 80% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $55.24 · 2021: $160 · 2022: $115 · 2023: $336 · 2024: $790 · 2025: $1,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,528 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,528.35 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $827.74 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $457.70 | 2021-2025 | Ilumya, Blu-U, Odomzo |
| Regeneron Healthcare Solutions, INC. | $337.17 | 2024-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $321.40 | 2019-2025 | Tremfya |
| Genzyme Corporation | $214.54 | 2023-2025 | |
| Lilly USA, LLC | $117.76 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $105.97 | 2023-2024 | Sotyktu |
| Amgen INC. | $103.44 | 2022-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $94.88 | 2024-2025 | Nemluvio, Aklief |
| Biofrontera INC. | $80.81 | 2020-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Organon LLC | $62.94 | 2024-2025 | |
| Ucb, INC. | $52.86 | 2021-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $51.58 | 2025 | |
| Pfizer INC. | $49.86 | 2025 | |
| Almirall LLC | $46.92 | 2022-2023 | Klisyri |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $44.74 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $38.50 | 2025 | Zoryve |
| Strata Skin Sciences, INC. | $23.18 | 2024 | Xtrac |
| Journey Medical Corporation | $21.89 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.88 | 2021 | |
| Tempus Ai, INC | $20.61 | 2024 | |
| Leo Pharma INC. | $18.89 | 2020 | |
| Sebela Pharmaceuticals INC. | $18.48 | 2021 | |
| Cipher Pharmaceuticals US LLC | $17.85 | 2025 | Natroba, Spinosad |
| Incyte Corporation | $17.72 | 2025 | Opzelura |
| Epi Health, LLC | $16.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.